The Prime Global agencies.
Working brilliantly in partnership with our clients
Operating out of eight office locations in the UK, US, Europe and New Zealand, our agencies bring an outstanding blend of skills and expertise to the Prime Global offering thanks to the dedicated people who drive them forward.
Each agency provides its clients with full-service medical communications support, delivering core competencies through teams that are carefully chosen to ensure success.
The agency structure of the group helps us to give you the excellent service, consistent approach and high standards of delivery you expect. Our structure also enables us to fully comply with the demands of client confidentiality without compromising operational agility.
While each agency has its own distinct personality, all share the Prime Global commitment to scientific and creative brilliance.
IRIS is a strategic consultancy, operating at group level. IRIS (Insights-Research-Innovation-Strategy) supports each Prime Global agency to provide ever more effective solutions to their clients, as well as working directly with clients on big-picture programs to deliver transformational change.
Prime Access is a specialist Market Access and HEOR consultancy, operating at group level. Partnering with the Prime Global agencies or consulting directly where needed, our experienced team share their first-hand knowledge of payer communications and drug development.
ONLY Oncology is a specialist oncology consultancy, operating at group level. Our oncology experts partner with the Prime Global agencies as needed, providing senior expert support and unique access to their external networks of expertise in specific tumour types.
Prime Omics is a technical and strategic consultancy to support clear and accurate reporting of molecular data in healthcare communications. Prime Omics provides expert guidance on how to decode and characterise data from biological molecules such as DNA (genomics), RNA (transcriptomics), and proteins (proteomics), as well as metabolic pathways (metabolomics) and microbes (microbiomics), and use that information to help improve patient outcomes.